529 related articles for article (PubMed ID: 16973256)
1. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Lombardi G; Cimini V; Zullo F
Fertil Steril; 2005 Jul; 84(1):154-61. PubMed ID: 16009171
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
4. [Effects of mifepristone on estrogen and progestin receptors in human uterine leiomyoma].
Wang H; Jin J
Zhonghua Fu Chan Ke Za Zhi; 2000 Feb; 35(2):79-81. PubMed ID: 11809103
[TBL] [Abstract][Full Text] [Related]
5. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
6. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
7. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.
Liu J; Matsuo H; Xu Q; Chen W; Wang J; Maruo T
Hum Reprod; 2007 May; 22(5):1253-9. PubMed ID: 17220163
[TBL] [Abstract][Full Text] [Related]
8. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
9. Different expression of estrogen receptors alpha and beta in human myometrium and leiomyoma during the proliferative phase of the menstrual cycle and after GnRHa treatment.
Wang H; Wu X; Englund K; Masironi B; Eriksson H; Sahlin L
Gynecol Endocrinol; 2001 Dec; 15(6):443-52. PubMed ID: 11826769
[TBL] [Abstract][Full Text] [Related]
10. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
11. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors.
Lindgren P; Bäckström T; Mählck CG; Ridderheim M; Cajander S
Int J Oncol; 2001 Jul; 19(1):31-8. PubMed ID: 11408919
[TBL] [Abstract][Full Text] [Related]
12. MIB-1 (Ki-67), estrogen receptor, progesterone receptor, and p53 expression in atypical cells in uterine symplastic leiomyomas.
Sun X; Mittal K
Int J Gynecol Pathol; 2010 Jan; 29(1):51-4. PubMed ID: 19952937
[TBL] [Abstract][Full Text] [Related]
13. Are there any differences in the expression of hormonal receptors and proliferation markers between uterine and extrauterine leiomyomas?
Sen N; Demirkan NC; Colakoglu N; Duzcan SE
Int J Surg Pathol; 2008 Jan; 16(1):43-7. PubMed ID: 18203783
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
15. Genic expression of the uterine leiomyoma in reproductive-aged women after treatment with goserelin.
Borsari R; Bozzini N; Junqueira CR; Soares JM; Hilário SG; Baracat EC
Fertil Steril; 2010 Aug; 94(3):1072-7. PubMed ID: 19481745
[TBL] [Abstract][Full Text] [Related]
16. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.
Walker CL; Burroughs KD; Davis B; Sowell K; Everitt JI; Fuchs-Young R
J Soc Gynecol Investig; 2000; 7(4):249-56. PubMed ID: 10964025
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
19. bcl-2 and p53 in endometrial adenocarcinoma.
Taskin M; Lallas TA; Barber HR; Shevchuk MM
Mod Pathol; 1997 Jul; 10(7):728-34. PubMed ID: 9237185
[TBL] [Abstract][Full Text] [Related]
20. Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells.
Yamada T; Nakago S; Kurachi O; Wang J; Takekida S; Matsuo H; Maruo T
Hum Reprod; 2004 Apr; 19(4):815-21. PubMed ID: 15033949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
